Track 14: Cancer, Malaria & TB Vaccines
Malaria keeps on guaranteeing an expected 2 to 3 million lives every year and to represent untold dismalness in the around 300 to 500 million individuals contaminated yearly. Jungle fever is viewed as a reappearing malady, due to a great extent to the spread of medication safe parasite strains, rot of medicinal services framework and challenges in executing and keeping up vector control programs in many creating nations. Four types of protozoan parasites cause jungle fever in people: Plasmodium falciparum, P. vivax, P. malaria, and P. ovale. P. falciparum is liable for most of passing’s and the vast majority of the extreme types of sickness, including cerebral jungle fever. 2 billion individuals inactively tainted with M. tuberculosis 5-10% tainted individuals progress to sickness 9 million new TB cases every year 1.5 million TB passings every year Equivalent to 20 traveller flying machine crashes every day. TB is transmitted by grown-ups with citatory sickness HIV tainted individuals worry about more prominent concern of ailment. Most elevated danger of movement from TB contamination to dynamic infection, and most exceedingly terrible TB horribleness and mortality, contrasted with more established youngsters and grown-ups.
- AS01 Vaccine
- RTS,S
Related Conference of Track 14: Cancer, Malaria & TB Vaccines
7th International Conference on Vaccines, Immunology and Clinical Trials
Track 14: Cancer, Malaria & TB Vaccines Conference Speakers
Recommended Sessions
- Track 01: Vaccines
- Track 02: Pediatric Vaccines
- Track 03: HIV Vaccines
- Track 04: Toxoid Vaccines
- Track 05: DNA & Synthetic Vaccines
- Track 06: Vaccines for Pregnant Women
- Track 07: Pediatric Vaccination
- Track 08: Zika Virus Vaccines
- Track 09: Vaccines for Unconventional Diseases
- Track 10: Vaccine Production & Development
- Track 11: Human Vaccines Against Infectious Diseases
- Track 12: Combination & Conjugate Vaccines
- Track 13: Vaccine Safety & Efficacy
- Track 14: Cancer, Malaria & TB Vaccines
- Track 15: RDT in Antibiotic Research
- Track 16: Side-effects of Vaccines
- Track 17: Vaccines Manufacturing Technologies
- Track 18: Vaccines Research and Clinical Trails
- Track 19: New Trends in Vaccines Development
Related Journals
Are you interested in
- Animal & Plant Derived Vaccines - Vaccine Immunology 2024 (France)
- Animal Models & Clinical Trials - Vaccine Immunology 2024 (France)
- Antibodies: Engineering & Therapeutics - Vaccine Immunology 2024 (France)
- Antiviral Therapies - Virology 2024 (Austria)
- Basic Immunology - Virology 2024 (Austria)
- Cancer, Malaria & TB Vaccines - Vaccine Immunology 2024 (France)
- Cellular Immunology & Latest Innovations - Vaccine Immunology 2024 (France)
- Challenges in Global Vaccination Programs - Vaccines R&D 2024 (Netherlands)
- Clinical Immunology - Virology 2024 (Austria)
- Clinical Trials: Safety, Efficacy, and Beyond - Vaccines R&D 2024 (Netherlands)
- Combination & Conjugate Vaccines - Vaccine Immunology 2024 (France)
- COVID19 Vaccines - VACCINE CONGRESS 2024 (Spain)
- Current Research & Future Challenges - Vaccine Immunology 2024 (France)
- Cutting-Edge Techniques in Vaccine Manufacturing - Vaccines R&D 2024 (Netherlands)
- DNA & Synthetic Vaccines - Vaccine Immunology 2024 (France)
- Emerging Infectious Diseases and Global Health - VACCINES WORLD 2024 (Canada)
- Emerging Viral Diseases - Virology 2024 (Austria)
- Epidemiology and Public Health - Virology 2024 (Austria)
- Ethical and Societal Aspects of Vaccination - VACCINES WORLD 2024 (Canada)
- Fish & Poultry Vaccines - Vaccine Immunology 2024 (France)
- Gene Editing for Vaccine Development - Vaccines R&D 2024 (Netherlands)
- Geriatric Immunization - Vaccine Immunology 2024 (France)
- Geriatric Vaccines - VACCINE CONGRESS 2024 (Spain)
- Global Vaccine Access - VACCINE CONGRESS 2024 (Spain)
- HIV Vaccines - Vaccine Immunology 2024 (France)
- Immune System and Non-Infectious Diseases - Vaccines R&D 2024 (Netherlands)
- Immunization in Special Populations - VACCINES WORLD 2024 (Canada)
- Immunodiagnostics and Monitoring Immune Responses - VACCINES WORLD 2024 (Canada)
- Immunogenetics and Genomics - Virology 2024 (Austria)
- Immunogenetics and Personalized Vaccinology - VACCINES WORLD 2024 (Canada)
- Immunology and Infectious Diseases: Current Landscape - Vaccines R&D 2024 (Netherlands)
- Immunology of Aging and Vaccination - Vaccines R&D 2024 (Netherlands)
- Immunology of Vaccines - VACCINE CONGRESS 2024 (Spain)
- Immunometabolism - Virology 2024 (Austria)
- Immunopathology and Host-Pathogen Interactions - VACCINES WORLD 2024 (Canada)
- Immunotherapy - Virology 2024 (Austria)
- Immunotherapy: Novel Strategies and Technologies - Vaccines R&D 2024 (Netherlands)
- Infectious Diseases and Immunity - Virology 2024 (Austria)
- Inflammation and Immune Response - Virology 2024 (Austria)
- Innate and Adaptive Immune Responses - VACCINES WORLD 2024 (Canada)
- Innovative Approaches to Vaccine Design - Vaccines R&D 2024 (Netherlands)
- Innovative Immunotherapies - VACCINES WORLD 2024 (Canada)
- Next Generation Vaccines - VACCINE CONGRESS 2024 (Spain)
- Next-Generation Vaccines: Advancements and Challenges - Vaccines R&D 2024 (Netherlands)
- Novel Vaccine Platforms - VACCINE CONGRESS 2024 (Spain)
- One Health Approach - VACCINE CONGRESS 2024 (Spain)
- Paediatric Vaccination - Vaccine Immunology 2024 (France)
- Paediatric Vaccines - VACCINE CONGRESS 2024 (Spain)
- Precision Medicine and Personalized Vaccines - Vaccines R&D 2024 (Netherlands)
- Public Health and Vaccination Programs - VACCINES WORLD 2024 (Canada)
- Public-Private Partnerships for Vaccine Research - Vaccines R&D 2024 (Netherlands)
- Regulatory Guidelines for Vaccine Approval - Vaccines R&D 2024 (Netherlands)
- The Future of Vaccinology: Trends and Prospects - Vaccines R&D 2024 (Netherlands)
- Travel & Edible Vaccines - Vaccine Immunology 2024 (France)
- Vaccination Strategies for Vector-Borne Diseases - VACCINES WORLD 2024 (Canada)
- Vaccine Adjuvants - VACCINE CONGRESS 2024 (Spain)
- Vaccine Clinical Trials - VACCINE CONGRESS 2024 (Spain)
- Vaccine Delivery Systems - VACCINE CONGRESS 2024 (Spain)
- Vaccine Development - Virology 2024 (Austria)
- Vaccine Development and Design - VACCINES WORLD 2024 (Canada)
- Vaccine Development for Emerging Diseases - VACCINE CONGRESS 2024 (Spain)
- Vaccine Economics and Market Access - VACCINES WORLD 2024 (Canada)
- Vaccine Education and Advocacy - VACCINES WORLD 2024 (Canada)
- Vaccine Equity - VACCINE CONGRESS 2024 (Spain)
- Vaccine Financing - VACCINE CONGRESS 2024 (Spain)
- Vaccine Hesitancy - VACCINE CONGRESS 2024 (Spain)
- Vaccine Hesitancy: Causes and Solutions - Vaccines R&D 2024 (Netherlands)
- Vaccine Immunogenicity - VACCINE CONGRESS 2024 (Spain)
- Vaccine Manufacturing - VACCINE CONGRESS 2024 (Spain)
- Vaccine Policy and Regulation - VACCINE CONGRESS 2024 (Spain)
- Vaccine Production & Development - Vaccine Immunology 2024 (France)
- Vaccine Safety - VACCINE CONGRESS 2024 (Spain)
- Vaccine Safety and Adverse Event Monitoring - VACCINES WORLD 2024 (Canada)
- Vaccine Surveillance - VACCINE CONGRESS 2024 (Spain)
- Vaccines - Vaccine Immunology 2024 (France)
- Vaccines & Autism - Vaccine Immunology 2024 (France)
- Vaccines against Drugs - Vaccine Immunology 2024 (France)
- Vaccines against Infectious Diseases - Vaccine Immunology 2024 (France)
- Vaccines Epidemiology - VACCINE CONGRESS 2024 (Spain)
- Vaccines for Immune Mediated Diseases - Vaccine Immunology 2024 (France)
- Vaccines for Non-Communicable Diseases - VACCINES WORLD 2024 (Canada)
- Vaccines for Pregnant Women & Neonates - Vaccine Immunology 2024 (France)
- Vaccines for Unconventional Diseases - Vaccine Immunology 2024 (France)
- Vaccines Immunology - VACCINE CONGRESS 2024 (Spain)
- Vectors, Adjuvants & Delivery Systems - Vaccine Immunology 2024 (France)
- Viral Diagnostics - Virology 2024 (Austria)
- Viral Genomics and Evolution - Virology 2024 (Austria)
- Viral Immunology - Virology 2024 (Austria)
- Viral Pathogenesis - Virology 2024 (Austria)
- Viral Vaccines - Virology 2024 (Austria)